| Business Summary | | EXACT
Sciences
Corporation
has
developed
proprietary
technologies
in
applied
genomics
that
will
assist
in
the
early
detection
of
colorectal
cancer
and
several
other
types
of
common
cancers.
The
Company
has
selected
colorectal
cancer
as
the
first
application
of
its
technology
platform
because
it
is
the
most
deadly
cancer
among
non-smokers,
curable
if
detected
early
and
has
been
studied
from
a
genomics
point
of
view.
The
Company
has
developed
proprietary
technologies
that
isolate
the
human
DNA
shed
from
the
colon
into
stool.
It
then
identifies
mutations
in
DNA
shed
from
abnormal
cells
associated
with
colorectal
cancer
and
pre-cancerous
lesions.
The
Company
has
conducted
blinded
clinical
studies
at
the
Mayo
Clinic
that
may
indicate
that
its
tests
are
able
to
detect
colorectal
cancer
more
accurately
in
patients
who
have
the
disease
at
an
earlier
stage
than
methods
available
for
mass
screening
for
colorectal
cancer. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | EXACT
Sciences
Corporation
has
developed
proprietary
technologies
in
applied
genomics
that
the
Company
believes
will
enable
the
early
detection
of
colorectal
cancer
and
several
other
types
of
common
cancers.
For
the
six
months
ended
6/30/01,
the
Company
reported
no
revenues.
Net
loss
totaled
$11.1
million,
up
from
$3.9
million.
Higher
loss
reflects
increased
personnel
expenses
and
professional
fees
and
higher
stock-based
compensation
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Stanley Lapidus, 51 Chairman | $287K | $105K | Don Hardison, 50 Pres,
CEO, Director | 407K | 400K | John McCarthy, Jr., 42 CFO,
Exec. VP | 50K | 300K | Stephen Read VP, Controller | -- | -- | David Nikka VP, Resources and Devel. | -- | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|